INDIANAPOLIS, IN -- (MARKET WIRE) -- May 03, 2007 -- Eli Lilly and Company (NYSE: LLY) today announced that data from a pooled analysis of three studies suggest that in patients with pain caused by diabetic nerve damage, or diabetic peripheral neuropathy, who are treated with Cymbalta (duloxetine HCl), improvements in both average daily pain and night pain severity were associated with less pain-related sleep interference than in those patients taking sugar pill. Results from the analysis of more than 1,000 patients were presented today at the annual meeting of the American Pain Society in Washington, D.C.
